TEC Assessments in Press

September 2009

The following Assessments and Special Report from the June 2009 Medical Advisory Panel (MAP) meeting are in press.

• Off-Label Use of Bevacizumab: Advanced Adenocarcinoma of the Pancreas
• Special Report: Evaluating Evidence Supporting a Role for Genetic Markers in Diagnosis, Determining Disease Predisposition, Prognosis, or Predicting Therapeutic Response
• Transcranial Magnetic Stimulation for Depression

Please note that the draft, “Genetic Testing for Hypertrophic Cardiomyopathy,” was tabled for action at a future meeting.

_____________________________________________________________________

NOTICE OF PURPOSE:  TEC Assessments are scientific opinions, provided solely for informational purposes. TEC Assessments should not be construed to suggest that the Blue Cross Blue Shield Association, Kaiser Permanente Medical Care Program or the TEC Program recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service; any particular course of treatment, procedure, or service; or the payment or non-payment of the technology or technologies evaluated.